BFM
RARE icon

Boothbay Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Boothbay Fund Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-108,700
Closed -$2.5M – 2405
2025
Q4 		$2.5M Buy
+108,700
New +$3.57M 0.04% 496
2025
Q3 		– Sell
-203,600
Closed -$7.4M – 2105
2025
Q2 		$7.4M Buy
203,600
+169,500
+497% +$6.11M 0.14% 189
2025
Q1 		$1.23M Buy
+34,100
New +$1.42M 0.03% 561
2020
Q3 		– Sell
-61
Closed -$477K – 1186
2020
Q2 		$477K Sell
61
-75
-55% -$4.96K 0.03% 589
2020
Q1 		$604K Buy
+136
New +$7.06K 0.05% 421

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Boothbay Fund Management's RARE Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 141,978 shares worth $2.97M. The stake represents 0.04% of the portfolio and ranks #480 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in RARE as recently as Q3 2025.

Boothbay Fund Management first reported a position in RARE in Q4 2019 and has held it in 9 quarters since. The position peaked at $3.03M in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Boothbay Fund Management held 141,978 shares of Ultragenyx Pharmaceutical worth $2.97M as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Boothbay Fund Management position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.04% of Boothbay Fund Management's portfolio in Q1 2026, its #480 holding.
  • Boothbay Fund Management first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and has held it in 9 quarters since.
  • Boothbay Fund Management's Ultragenyx Pharmaceutical position peaked at $3.03M in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.